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Reduced responsiveness of platelets to prostacyelin, re-
ported in vitro in patients with coronary artery disease,
has been thought to be a factor predisposing toward
coronary thrombosis and vasospasm lis a result of en-
hanced in vivo release of cyclic endoperoxides and
thromboxane A2 by the platelets. In this study, specific
binding of prostacyclin to intact platelets was determined
in patients with coronary artery disease by direct binding
studies using 9-3H-prostacyclin sodium salt. In addition,
the inhibitory effect of prostacyclin on primary aggre-
gation induced by adenosine diphosphate and cyclic
adenosine monophosphate (cyclic AMP) accumulation
stimulated by prostacyclin was examined. Twenty pa-
tients with angiographically documented coronary ar-
tery disease and stable angina, 8 patients with acute
myocardial infarction, 14 healthy volunteers and 10 pa-
tients with normal angiograms were studied.
In patients with stable angina, binding capacity and
affinity of platelet prostacyclin binding sites and pros-
tacyclin-induced cyclic AMP accumulation were not dif-
ferent from those of control subjects. In patients with
acute myocardial infarction, however, binding capacity
of platelet prostacyclin receptors was significantly re-
duced (0.69 ± 0.45 versus 1.35 ± 0.37 pmol/Iu" plate-
lets, p = 0.001) and the postreceptor response, repre-
There is considerable evidence (1,2) to support the concept
that platelet activation plays an important role in the patho-
genesis of cardiovascular disorders. After pacing-induced
angina (3,4) and in patients with angina at rest (5), increased
concentrations of thromboxane Bz have been found in coro-
nary sinus blood and have been interpreted to indicate plate-
let activation in the coronary vasculature during ischemia.
As shown by angiographic investigation (6,7), coronary
thrombosis or va.sospasm (or both) is a predominant finding
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sented by platelet responsiveness to prostacyclln and
prostacychn-lnduced cyclic AMP synthesis, was im-
paired.
Because all patients with myocardial infarction were
receiving intravenous heparin and nitroglycerin, which
might interfere with platelet prostacyclin binding, com-
petition experiments were performed in vitro. Neither
heparin (3 to 250 IU/ml) nor nitroglycerin (0.8 to 22 ILM)
displaced specifically bound 9-3H-prostacyclin. t-Epi-
nephrine in concentrations up to 10 ILM also exhibited
no competition with specific platelet prostacyclin bind-
ing.
Thus, the data provide no evidence that reduction of
platelet prostacyclin receptor density or prostacyclin-
induced cyclicAMPaccumulation is an additional patho-
genetic mechanism predisposing to thrombotic occlusion
or vasospasm in stable angina. The reduction of platelet
prostacyclin binding observed in acute myocardial in-
farction, however, might induce further intracoronary
thrombotic events or a decrease in coronary blood flow
due to vasospasm, particularly in combination with lo-
cally reduced prostacyclin synthesis in atheromatous
plaques.
(J Am Coli Cardiol 1986;8:259-66)
in the early hours of myocardial infarction. Arachidonate
metabolites produced by the platelet cyclooxygenase path-
way are known for their vasospastic, proaggregatory and
arrhythmogenic properties (8-10). On the other hand, ef-
ficient vasodilation and inhibition of platelet function can
be achieved by prostacyclin, an unstable arachidonate me-
tabolite produced by the endothelium (11). The relative
concentrations of prostacyclin and thromboxane Az at the
site of thrombus formation have been postulated to be es-
sential determinants regulating hemostatic balance and vas-
cular tone (12).
Enhanced susceptibility of platelets to proaggregating
stimuli with the concomitant increase of eicosanoid for-
mation might explain the increased thromboxane formation
in the coronary vasculature during ischemia (13-15). How-
ever, impaired release of prostacyclin by damaged endo-
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thelium (16) and, in particular, reduced responsiveness of
platelets to prostacyclin (17,18) might favor additionally the
in vivo synthesis of platelet-derived endoperoxides and
thromboxane A2. Specific platelet prostacyclin receptors have
been shown to exist (19,20). In platelets, ligand-receptor
coupling is known to cause activation of platelet adenylate
cyclase (21). The resulting increase of intracellular cyclic
adenosine monophosphate (cyclic AMP) inhibits platelet
phospholipases by regulation of free cytosolic calcium and
controls the synthesis of cyclic endoperoxides (PGG2, PGH2)
and thromboxane (22,23). Thus, binding of prostacyclin to
platelets seems to have a key role in the modulation of local
interactions between platelets and the endothelium.
The present study was performed to compare specific
platelet 9-3H-prostacyclin binding (affinity and number of
binding sites) in patients with acute myocardial infarction,
patients with stable angina, angiographically normal patients
and healthy volunteers. Furthermore, the postreceptor re-
sponses, that is, prostacyclin-induced cyclic AMP accu-
mulation and antiaggregatory effectiveness of prostacyclin
on adenosine diphosphate-induced platelet aggregation, were
determined.
Methods
Subjects. The study subjects consisted of four subgroups:
Group I comprised 14 healthy young men, all nonsmokers,
with no family or personal history of peripheral vascular or
coronary artery disease (24). None had hypertension or el-
evated plasma lipids, or was taking long-term maintenance
or intermittent medication or any drug known to interfere
with platelet function.
Group II comprised 20 patients hospitalizedfor coronary
angiography. All had a history of typical exertional chest
pain diagnosed as angina pectoris. None had diabetes or a
history of peripheral vascular disease. Ten patients had a
previous myocardial infarction with residual electrocardio-
graphic changes (Q waves). Coronary angiography was per-
formed using the Judkins technique. The angiograms were
reviewed by at least two experienced cardiologists who were
unaware of the biochemical data. The extent of the stenoses
was graded and the angiographic severity of coronary artery
disease was calculated using the Gensini score (25). All 20
patients were taking oral isosorbide dinitrate (20 to 60 mg,
three times a day) and a beta-adrenergic blocker (propran-
olol, 20 to 60 mg, three times a day or metoprolol, 50 to
100 mg, twice a day). Ten patients were taking oral nifed-
ipine (10 to 20 mg, three times a day).
Group III comprised 10 patients who underwent coronary
angiography to exclude coronary artery disease, concom-
itant valve disease or cardiomyopathy. None had severe
heart failure or thromboembolic episodes, conditions fre-
quently associated with intravascular platelet activation
(26,27). All had normal coronary arteries. Seven of the 10
patients were taking beta-blocker (20 to 60 mg propranolol,
three times a day or metoprolol, 50 to 100 mg, twice a
day), all patients were receiving oral isosorbide dinitrate
(20 to 60 mg, three times a day) and 5 patients were taking
oral nifedipine (10 to 20 mg, three times a day).
Group IV comprised eight patients with acute myocardial
infarction diagnosed by electrocardiographic criteria and
serial enzymatic measurements of plasma creatine kinase
and creatine kinase, MB fraction. All patients were hos-
pitalized Within 12 hours after the onset of typical chest
pain, which was not relieved by sublingual nitroglycerin.
Three patients were studied on day 3 and five patients on
day 2 after the onset of symptoms. At the time of blood
withdrawal they had been receiving an intravenous medi-
cation consisting of porcine mucosal heparin (25,000 IU/24
h) and glycerol trinitrate (2 to 5 mg/h) for at least 24 hours.
Six patients received additional nifedipine (10 to 20 mg,
three times a day). None of the patients with myocardial
infarction was taking a beta-blocker at the time of sample
collection; beta-blockers were discontinued in two of these
patients 48 hours before the investigation.
Sample collection and platelet preparation. All sub-
jects gave their informed consent. After overnight fasting
and cessation of oral medication, 200 ml of venous blood
was obtained between 8 and 9 AM by clean venipuncture
(19 gauge needle) and anticoagulated with 3.8% trisodium
citrate (1 + 9, vol/vol).
Platelet-rich plasma was prepared by low speed centrif-
ugation (180g, 15 minutes) and the platelet count was ad-
justed to 3 x 1011 plateletslliter with autologous platelet-
poor plasma. For prostacyclin binding studies, platelets were
washed once in 0.2 M Tris-maleate, pH 5.9, and resus-
pended in phosphate-buffered saline solution (0.9% sodium
chloride and 0.154 M phosphate buffer, pH 7.4) to obtain
a platelet count of 1 x 1012/liter.
Materials. The following were obtained from NEN
(Dreieich, West Germany): 9-3H-PGh-methylester, 2,8-3H-
adenine, 8-14C-adenosine-3' ,5'-cyclic phosphate and fruc-
tose-l''Ctl.ll-sucrose. Adenosine-5-diphosphate and unla-
beled prostaglandins were purchased from Sigma Biochem-
icals (Munich, West Germany) and adenosine-3' ,5'-
monophosphate sodium salt was from PL-Biochemicals
(Freiburg, West Germany). Prostaglandin 12 (PGI 2) sodium
salt was dissolved in 50 mMTris-hydrochloric acid, pH 8.5,
and kept frozen at - 80cC. For binding experiments, 9-3H-
PGI2-methylester was hydrolyzed to prostacyclin sodium
salt as described by Hsi et al. (28). Tritium-labeled and
unlabeled ZK 36374 were a generous gift from Dr. E. Schil-
linger (Schering AG, Berlin, West Germany). AG50W-X4
resin was obtained from Bio-Rad Laboratories (Munich,
West Germany). All other reagents were of analytic grade
and were obtained from Merck (Darmstadt, West Germany).
Radioactivity was counted in 5 ml Instagel (Packard) in
a Tri-Carb scintillation counter (Packard). Double label
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B = Bma• X U(K o + L) + C X L,
Figure 1. Representative prostacyclin binding saturation curve
(e ) and dose-response curve ofprostacyclin (PG)12-inducedcyclic
adenosine monophosphate (cAMP) accumulation (O) in intact
washed platelets resuspended in phosphate-buffered saline solu-
tion. incorp. = incorporated.
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Figure 2. Displacement of specific binding of 9-3H-prostacyclin
(9-3H-PGh) by prostaglandins, nitroglycerin and t.-epinephrine.
Platelets were incubated with 3nM9-3H-PGI2and increasing amounts
of unlabeled PGh (h), PGE1(EI ), 6-oxo-PGE I (oxo-Ej), PGD2(D2) , 6-oxo-PGF I (F lu), nitroglycerin (NTG) and L-epinephrine
(L-EPIN). Specific bindingof labeled PGh was determined in the
presence of 20 IJM PGh and was 65 frnol/H)? platelets. (Data
points represent means of at least three determinations.)
where KD = equilibrium dissociation constant; L = total
ligand concentration; Bma• = binding capacity; B = total
bound ligand; and C X L = nonspecific binding.
Characterization of platelet prostacyc1in binding. The
equilibriumdissociationconstant of 9-3H-prostacyclin bind-
ing (KD = 52 nM) was found to be in close agreement with
the dose of prostacyclin required for half-maximal stimu-
lation of cyclic AMP accumulation in 3H-adenine prelabeled
platelets (53 ± 6 nM, n = 3) (Fig. 1). To verify whether
platelet prostacyclin binding was specific, the displacement
of 3 nM 9-3H-PGIz by prostaglandin E1 (PGEd, 6-oxo-
PGEIo 6-oxo-PGF1a and PGD2 was measured: PGE1and 6-
oxe-PGE1share the platelet prostacyclin receptor, but their
affinity is much lower as compared with PGIz (500 and
1,600 nM, respectively). PGDz and 6-oxo-PGF1a exhibited
no competition with platelet prostacyclin binding in con-
centrations up to 10 p.,M (Fig. 2).
The kinetics ofplatelet prostacyclin binding were inves-
tigated with the stable prostacyclin analog ZK 36374. The
association rate of 10 nM 3H-ZK 36374 was measured at
20°C. The observed rate constant (Kobs) , as calculated from
the slope of pseudo-first order kinetics, was 8.5 x 10- 3
s- I. The rate constant of dissociation (K_1)of the ligand-
receptor complex was determined by measurements of the
time course of 3H-ZK 36374 displacement after addition of
unlabeled ZK 36374 (20 p.,M final concentration). A half-
life of 140 seconds was found, from which K_ 1 = 4.9 X
10-3 S- I could be determined. The forward rate constant
is given by K+1 = (Kobs - K_ 1)/(Iigand) and was 3.6 x
105 mol-I s - I . Thus, the true dissociation constant of ZK
36374 binding, which is given by the ratio K_1/K+ h could
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counting efficiencies were 52% for tritium and 80% for
carbon-14.
Platelet prostacyclin receptor assay. Platelet prosta-
cyelin binding was determined using tritiated prostacyclin
sodium salt (specific activity 10Cilmmo\). Aliquots of washed
platelets were incubatedwith 3 nM 9-3H-prostacyclin (about
100,000disintegrations/min) and appropriateconcentrations
of unlabeled prostacyclin up to 20 JLM. With this range of
ligand concentrations, complete saturation of the binding
sites was accomplished (Fig. I). The extracellular space
was monitored with 14C-sucrose as described by Siegl et al.
(19). Incubations were carried out in a final volume of 1
ml at 20°C for 5 minutes and terminated by centrifugation
(l4,000g, 20 seconds). Radioactivity in pellets and in su-
pernatants was determined by liquid scintillation counting.
Bound 9-3H-prostacyclin was calculated after correction for
spillover, background and extracellular space. Nonspecific
binding, determined in the presence of 20 p.,M unlabeled
prostacyelin, was 20 to 50% ofthe total bound radioactivity.
In all experiments the inflection point of the binding satu-
ration curve was reached (29). To determine the reproduc-
ibility of the method, platelet prostacyclin receptors of three
healthy individuals were reinvestigatedafter 3 to 12months.
The interassay variance of the binding capacity (Bma. ) was
12 ± 3%.
Calculation of receptor data. Binding capacity and
equilibrium dissociation constants were calculated by com-
puterized analysis of the competition curves (NONLIN) us-
ing one or two binding site models based on the law of mass
action. The analysis of the competition curves, assuming a
two site model, resulted in identical values of equilibrium
dissociation constants (Ko , = K0 2) . Furthermore, the two
site model did not improve the "goodness of fit" when
saturation analysis was performed (30). Thus, we decided
to interpret the experimental data assuming a single binding
site and nonspecific binding according to the formula:
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be calculated to be 14 nM. This is in agreement with the
equilibrium dissociationconstant of ZK 36374 binding, which
amounted to 10 to 15 nM, indicating that this prostacyclin
analog has a two to three times higher affinity to prostacyclin
binding sites than prostacyclin.
To investigate whether platelet prostacyclin receptors are
regulated by their agonists, citrated platelet-rich plasma was
incubated for 12 hours at 20°C with ZK 36374 in a final
concentration of 100 nM. The incubation was terminated
by thorough washing to remove the agonist. Complete re-
moval was checked by adding 3H-ZK 36374. Platelets prein-
cubated with 100 nM ZK 36374 bound less of the stable
prostacyclin analog compared with control platelets obtained
from the same donors (-42 ± 7%, n = 3). This desen-
sitization process has been demonstrated to be time- and
dose-dependent (tl/2 - 60 minutes, ED50 ~ 50 nM).
Cyclic AMP accumulation in platelets. Platelet-rich
plasma was prelabeled with 0.6 pM 3H-adenine (specific
activity 25 Ci/mmol). Incubations of prelabeled platelet-rich
plasma with various concentrations of P0I2 were carried
out at 37°C for 10 minutes and were terminated by the
addition of 50% (wtlvol) trichloroacetic acid containing ap-
propriate amounts of l4C-cyclic AMP to monitor recovery
during the following purification steps. 3H-cyclic AMP was
isolated by chromatography on AG50W-X4 (H+ form) and
subsequently treated with zinc sulfate and barium hydrox-
ide. The identity of the isolated 3H-cyclic AMP was dem-
onstrated by phosphodiesterase hydrolysis, and the amount
formed expressed as percent of total radioactivity incor-
porated into the platelets.
Inhibitory effect of prostacyclin on adenosine di-
phosphate-induced aggregation. Platelet-rich plasma
(3 x lO!' platelets/liter) was stirred in an aggregometer
(Fresenius, Homburg , West Germany) with various amounts
of prostacyclin for 90 seconds at 37°C before adenosine
diphosphate was added to give a final concentration of 0.6
/-LM. The primary aggregation induced by adenosine di-
phosphate was recorded and the dose of prostacyclin re-
quired for half-maximal inhibition (IC50) was calculated after
legit-log transformation.
Statistics. All results are expressed as means ± I SD.
Statistical analysis was performed by nonparametric statis-
tics (Mann-Whitney test); probability (p) values less than
0.01 were considered to be significant.
Results
Platelet prostacyclin binding and the inhibitory effect
of prostacyclin on adenosine diphosphate-induced ag-
gregation in vitro. The data of binding capacity (8 max) and
affinity (KD) of platelet prostacyclin binding sites, the an-
tiaggregatory effects of prostacyclin (IC50) and the extent
and localization of coronary heart disease determined by
angiography from patients with stable angina are listed in
Table I. Prostacyclin binding data, IC50 and diagnosis of
patients with normal angiograms are shown in Table 2.
Table 1. Platelet Prostacyclin Binding, Antiaggregatory Potency of Prostaglandin hand Angiographic Findings in 20 Patients With
Stable Angina
Extent* and Previous
Age ICso Bmax KD Localization Infarctiont
Case (yr) (nM) (pmol! I09plts) (nM) of CAD (mo) GS
I 50 1.63 1.67 48 2 (RCA, LAD) 36
2 45 2.41 1.51 62 3 (RCA,LAD,LCx) 4 35
3 56 1.18 1.10 84 2 (LAD,LC) 6 31
4 54 2.53 2.97 III 2 (RCA,LCx) 4
5 48 1.51 1.16 44 2 (RCA,LAD) 12
6 47 2.48 0.63 41 I (Diag) 4
7 53 2.02 1.67 33 2 (RCA,LCx) 12 4
8 53 0.81 1.29 67 2 (RCA,LAD) 22 52
9 51 0.85 1.90 104 3 (RCA,LAD,LCx) 3 59
10 54 1.32 2.14 144 3 (RCA,LAD,LCx) 28
II 49 1.22 2.15 114 2 (RCA,LCx) 34
12 59 1.13 1.21 77 3 (RCA,LAD,LCx) 39
13 52 1.54 1.06 70 I (LAD) 10
14 60 1.06 1.18 68 2 (RCA,LAD) 19
15 61 1.65 2.03 90 3 (RCA,LAD,LCx) 7 35
16 54 1.05 1.24 59 2 (RCA, LAD) 4 60
17 53 1.08 1.74 68 3 (RCA,LAD,LCx) I 41
18 57 1.39 1.41 88 2 (LAD,RCA) I 49
19 55 0.82 1.10 54 3 (RCA,LAD,LCx) 32
20 51 0.92 0.74 26 I (LAD) 3
*Number of vessels involved with stenosis greater than 50%. [Duration after myocardial infarction. Bmax and KD = binding capacity and affinity,
respectively, of platelet prostacyclin receptors; CAD = coronary artery disease; Diag = ramus diagonalis; GS = Gensini coronary artery score; ICso
= dose of prostacyclin required for half-maximal inhibition of platelet aggregation; LAD = left anterior descending coronary artery; LC = left main
coronary artery; LCx = left circumflex coronary artery; pits = platelets; RCA = right coronary artery; = no previous infarction.
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Table 2. Platel et Prostacycl in Binding and Diagnosis of 10
Patie nts With Normal Coronary Angiograms
Age ICso Bma, KD
Case (yr) (nM) (pmol!I09phs) (nM) Diagnosi s
I 60 1.62 1.76 104 Normal
2 51 1.18 1.67 48 Normal
3 55 1.26 0 .92 64 MVD
4 36 1.23 1.28 73 CM
5 55 0.80 1.86 56 CM
6 53 1.02 1.12 57 MVO
7 41 0.92 0.74 26 Normal
8 45 1.16 2.24 110 MVO
9 63 1.47 1.86 7 1 CM
10 44 1.07 1.5 1 52 AVO
AVD = aortic valve disease; CM = cardiomyopathy; MVD = mitral
valve disease; other abbreviations as in Table I .
Patients with stable angina were not different from the
age-matched control subjects with normal angiograms and
the young healthy volunteers with respect to binding ca-
pacity, but binding affinity in these patient s was lower than
that found in young healthy volunteers. Nevert heless , no
statistically significant difference was observed when com-
paring patients with stable angina with age-matched control
subjects with norma l angiograms . The inhibitory effect of
prostacyclin on platelet aggregation induced by adenosine
diphosp hate also did not diffe r from that in control subjects
(Table 3). There is obviously no correlation between the
extent and severity of coronary artery disease and platelet
prostacyclin binding data or in vitro responsiveness to pros-
tacyclin (Table 2).
In patients with acute myocardial infarction, however,
platelet prostacyclin binding capacity was significantly re-
duced (by 49%, P = 0.001), but binding affinity did not
differ from that in control subjects . In the two patients in
whom beta-blockade was stopped 2 days before the inves-
tigation, the binding capacity of platelet prostacyclin re-
ceptors was 1.17 and 0.24 pmol/It)? platele ts, respectively .
The reduction of plate let prostacyclin receptor density in
acute myocardial infarction was demonstrated to be revers-
ible . Two patients were restudied at day 26 and day IS ,
respectively, after myocardial infarction: the binding ca-
pacity of both had returned to normal levels (1. 80 and 1.41
pmol! I09 platelets).
In patients with acute myocardial infarction, the inhibi-
tory effect of prostacyclin on platelet aggregation induced
by adenosine diphosphate was also reduced (lCso increased
by 67%). Primary platelet aggregation, determined by change
of optical density after addition of 0.6 JLM adenosine di-
phosphate , was not enhanced in this group (Table 3).
To rule out direct prostacyclin binding impairment due
to heparin, which was given intravenously to all patients
with myocardial infarction , two types of in vitro experiments
were carried out: I) Washed platelets from healthy volun-
teers were incubated with 3 oM labeled prostacyclin and
increasing amounts of porcine mucosal heparin (3 to 250
IV/mI) . No displacement of specifically bound prostacyclin
by heparin could be demonstrated . 2) Citrated platelet-rich
plasma was incubated with 4 IU/ml porcine mucosal hep-
arin , a concentration clearly above expected plasma levels
after 25 ,000 IU124 hours of intravenous heparin . After 30
minutes of incubation at 30°C, platelets were washed and
the prostacyclin binding capacity was determined. No dif-
ferences were observed in binding capacity and affinity be-
Table 3. Platelet Prostacyclin Bindi ng, Antiaggregatory Potency of Prostagl and in h, Platelet
Ag gregation Induced by Adenosine Diphosphate (A DP) and Plasma Lipids in the Four
Subg roups of Subjects
Group
I II III IV
Healthy Normal Stable Myocardial
Volunteers Angiograms Angina Infarction
(n = 14) (n = 10) (n = 20) (n = 8)
Bma. (prnol/ Hl''plts) 1.35 ± 0.37 1.50 ± 0.47 1.51 ± 0.54 0.69 ± 0.45
(0 .300/0.42 1) (0.00110.003)
K D (nM) 52 ± 13 66 :!: 25 74 ± 28 42 ± 25
(0 .006/0.2 14) (0 . 123/0 .038)
ICso (nM) 1.12 ± 0. 22 1.17 ± 0 .24 1.43 ± 0 .54 1.87 ± 0 .59
(0 .049/0. 136) (0 .005/0.003)
ADP (% LT) 15.2 ± 3.8 13.7 ± 4.6 15.2 ± 4.4 14.2 ± 3.6
(0 .500/0 .079) (0.263/0.313)
Cholesterol (rnM) 4.12 ± 0.67 4.89 ± 1.0 4.89 ± 0.62 4.32 ± 0.90
(0 .003/0. 372) (0 .47 110 .084)
Triglycerides (rnM) 1.49 ± 0.63 1.16 :!: 0.67 1.67 ± 0.67 1.30 ± 0.76
(0.039/0 .022) (0 .457/0 .395)
Age (yr) 31 ± 3 54 ± 8 55 ± 6 56 ± 8
Sex (M /F) 14/0 10/0 20/0 7/1
Data are given as mean ± SD; probability values are given in parentheses (III to IV versus IIIII to IV
versus II). F = female ; LT = light transmission; M = male; other abbreviat ions as in Table I.
264 JASCHONEK ET AL.
PLATELET PROSTACYCLIN BINDING
JACC Vol. 8. NO.2
August 1986:259-66
tween heparin-incubated platelets and control platelets ob-
tained from the same donor.
Further competition experiments showed no evidence that
nitroglycerin in concentrations ranging from 0.8 to 22 p.,M
interfered with specific prostacyclin binding. Also, t.-epi-
nephrine did not displace specifically bound prostacyclin in
concentrations of up to 10 p.,M (Fig. 2).
Prostacyclin-induced cyclic AMP accumulation in 38_
adenine prelabeled platelets. In intact platelets, more than
90% of cyclic AMP synthesized after stimulation of platelet
adenylate cyclase is hydrolyzed by phosphodiesterases. This
regulation of cyclic AMP levels is not apparent when aden-
ylate cyclase activity in platelet membranes is being mea-
sured. Because the determination of the amount of immu-
noreactive cyclic AMP in platelet-rich plasma is compromised
by the high background levels of plasma cyclic AMP, pros-
tacyclin-induced platelet cyclic AMP synthesis was mea-
sured using the 3H-adenine prelabeling technique.
Six healthy volunteers (group I), nine patients with stable
angina (group II) and four patients with acute myocardial
infarction (group III) were investigated. The dose of pros-
tacyclin required for doubling the cyclic AMP content of
platelets (EC200 ) was similar in groups I and II (5.2 ± 0.4
versus 5.3 ± 1.7 nM). However, the four patients with
acute myocardial ischemia required considerably more pros-
tacyclin for doubling the cyclic AMP of their platelets (22.0
± 4.5 nM). The increase of cyclic AMP did not differ in
groups I and 11(17.3 ± 2.1 versus 18.3 ± 2.6 times greater
increase in the presence of 100 nM prostacyclin) (Fig. 3).
In the patients with acute myocardial infarction, however,
prostacyclin caused a less pronounced increase in intracel-
lular cyclic AMP (5.5 ± 1.0 times greater).
Figure 3. Prostaglandin Iz-induced cyclic adenosine monophos-
phate (cAMP) accumulation in platelet-rich plasma prelabeled with
3H-adenine in healthy volunteers (e), patients with stable angina
(0) and acute myocardial infarction (6). Data are given as increase
of intracellular cyclic AMP content relative to basal levels, which
were not different among the groups and were less than 0.1% of
total radioactivity in the platelets. Symbols represent means ±
SD.
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To rule out the possibility that heparin interferes with
the prostacyclin-induced cyclic AMP synthesis in intact
platelets, we showed that the addition of 60 IU/ml heparin
had no influence on cyclase stimulation by 10 nM prosta-
cyelin.
Discussion
In preliminary experiments, binding of prostacyclin to
intact platelets was found to be linearly correlated with
platelet number and was saturable, reversible and specific.
Thus, it met all criteria for a specific binding site. The
equilibrium dissociation constant of prostacyclin binding
determined by direct binding studies was in close agreement
with the dose of prostacyclin required for half-maximal stim-
ulation of cyclic AMP synthesis in platelets. The evaluation
of prostacyclin binding data by nonlinear fitting, using bind-
ing models based on the law of mass action, did not show
a significantly better fit by a two binding site model. There-
fore, in contrast to previous reports (19,20), binding data
were evaluated assuming a single binding site and nonspe-
cific binding (30).
Stable angina. In patients with stable angina and an-
giographically documented coronary artery disease, no al-
teration of binding capacity and affinity for platelet pros-
tacyclin receptors was found. The prostacyclin-induced cyclic
AMP accumulation in intact platelets, which reflects aden-
ylate cyclase as well as phosphodiesterase activity, was
comparable in patients with stable angina and in young
healthy control subjects. In contrast to other investigators
(17,18), we did not find a significant difference in platelet
responsiveness to prostacyclin. This might be due to dif-
ferences in methods and patient selection (2). We deter-
mined the inhibitory effect of prostacyclin on primary plate-
let aggregation induced by adenosine diphosphate, because
secondary aggregation elicited by adenosine diphosphate
depends on the synthesis of cyclic endoperoxides and throm-
boxanes (31) and synthesis of thromboxane B2 has been
demonstrated to be increased in patients with ischemic heart
disease (14, IS). Furthermore, secondary aggregation seems
to be of questionable physiologic relevance because it occurs
only in a calcium-depleted medium, such as citrated platelet-
rich plasma (32). It also must be emphasized that patients
with stable angina and control patients with negative an-
giographic findings were comparable with respect to their
plasma lipids, age, medication and sample collection, fac-
tors that might modify the sensitivity of platelets to pros-
tacyclin (33,34).
Acute myocardial infarction. Patients with acute myo-
cardial ischemia exhibited a considerably lower platelet re-
sponsiveness to prostacyclin and prostacyclin-induced cyclic
AMP accumulation. Because heparin was given to all these
patients, its effects on platelet phosphatidylinositol metab-
olism and prostaglandin-stimulated adenylate cyclase activ-
ity could account for these observations (35,36). However,
there was no evidence that heparin interfered with prosta-
lACC Vol. 8, No.2
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cyclin-induced cyclic AMP accumulation when intact plate-
lets were studied instead of platelet membranes. Because
adenylate cyclase is presumed to be localized at the inner
surface of the platelet membrane, a possible explanation
could be that highly charged molecules like heparin probably
have limited, if any, access to the enzyme in intact cells .
Although heparin did not interfere with platelet prostacyclin
binding as determined in vitro by competition experiments ,
reduced binding capacity of the binding sites was found in
patients with myocardial infarction. In addition, competition
experiments showed no displacement of specifically bound
prostacyclin by nitroglycerin or L-epinephrine. Thus, the
reduced antiaggregatory effectiveness and the impaired cyclic
AMP accumulation after addition of prostacyclin most likely
reflect impaired receptor response due to reduction of pros-
tacyclin receptor density.
The reason for the reduced binding capacity ofplatelet
prostacyclin receptors in acute myocardial infarction re-
mains unknown. The increased vascular prostacyclin bio-
synthesis in patients with severe atherosclerosis and the
concomitant platelet activation stimulated the speculation
that agonist-induced prostacyclin receptor regulation might
occur in vivo, because reduced platelet responsiveness to
prostacyclin has been observed in these patients (37,38). If
indeed there is an agonist-induced receptor regulation, it is
conceivable that platelet prostacyclin receptor density is un-
changed in patients with stable angina because urinary ex-
cretion of dinor-prostacyclin metabolites is not altered in
this group (37). In patients with acute myocardial infarction,
increased urinary excretion of 6-oxo-PGF1,,, the stable hy-
drolysis product of prostacyclin, was reported (39). How-
ever , urinary excretion of this compound reflects complex
renal prostaglandin synthesis and excretion and is not a
reliable estimation of systemic vascular prostacyclin for-
mation (40,41), The influence of intravenous nitroglycerin,
which was given to all patients with acute myocardial in-
farction, on vascular prostacyclin synthesis is controversial
(42-44) . Nevertheless. because intravascular platelet acti-
vation is a frequent finding during myocardial infarction as
shown by beta-thromboglobulin determinations, shortened
platelet survival and increased urinary excretion of 2,3-
dinor-thromboxane B2 (45-47), one might expect that pros-
tacyclin biosynthesis is increased (37) . Recently, this con-
cept has been substantiated by the determination of urinary
excretion of 2,3-dinor-6-oxo-PGF la in patients with acute
myocardial infarction and unstable angina (48). Further-
more, as shown by in vitro experiments (see Methods), there
is indeed some evidence that platelet prostacyclin receptors
are regulated by agonist-induced receptor changes: incu-
bation of platelet-rich plasma with the stable prostacyclin
analog ZK 36374 resulted in a time- and dose-dependent
loss of receptors without significant changes in binding af-
finity. Thus it seems unlikely that prostacyclin causes up-
regulation of its own binding sites, as postulated by Neri
Serneri et al. (49),
Conclusions. Our data provide no evidence that in pa-
tients with stable angina a loss of prostacyclin receptors
might be a further pathogenetic factor predisposing to throm-
botic occlusion or vasospasm. The impairment of platelet
prostacyclin binding in patients with myocardial infarction
could favor the accumulation of platelets in the poststenotic
segment of the coronary artery . It has been suggested that
these platelet aggregates are responsible for cyclic flow re-
duction as a result of release of thromboxane A2 (50). In
acute myocardial infarction, application of prostacyclin or
its stable analogs has been considered a promising thera-
peutic approach (51,52). Long-term application of prosta-
cyclin, however, is followed by desensitization of platelets
against the antiaggregatory effects of prostacyclin and pros-
tacyclin-induced cyclic AMP accumulation (53,54). Be-
cause platelet prostacyclin binding is already reduced in
acute myocardial infarction, one might expect an enhanced
rebound effect , resulting in hyperaggregability of platelets
after cessation of prostacyclin therapy , with potential reoc-
elusion and infarct extension . Thus, rebound effects should
be avoided by slowly tapering off prostacyclin infusion;
overlapping treatment with platelet inhibitors may be an
alternative approach.
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